Are caregivers ready for digital? Caregiver preferences for health technology tools to monitor medication adherence among patients with serious mental illness

Felicia Forma¹*, Kevin Chiu², Jason Shafrin³†, Dusica Hadzi Boskovic⁴ and S Phani Veeranki⁵†

Abstract

Background: Adherence to antipsychotic medication is critical for bipolar disorder (BPD), major depression (MDD) and schizophrenia (SCZ) patients. Digital tools have emerged to monitor medication adherence along with tracking general health. Evidence on physician or patient preferences for such tools exists but is limited among caregivers. The study objective was to assess preferences and willingness-to-pay (WTP) for medication adherence monitoring tools among caregivers of SMI patients.

Methods: A web-based survey was administered to caregivers of adult SMI patients. Twelve discrete choice questions comparing adherence monitoring tools that varied across two attribute bundles: (1) tool attributes including source of medication adherence information, frequency of information updates, access to adherence information, and physical activity, mood, and rest tracking, and (2) caregiver monthly out-of-pocket cost attribute were administered to caregiver respondents. Attributes were parameterized for both digital and non-digital tools. Random utility models were used to estimate caregivers’ preferences and WTP.

Results: Among 184 study-eligible caregivers, 57, 61 and 66 participants cared for BPD, MDD, and SCZ patients, respectively. Caregivers highly preferred (odds ratio (OR): 7.34, 95% confidence interval (CI): 5.00–10.79) a tool that tracked medication ingestion using a pill embedded with an ingestible event marker (IEM) sensor and tracked patients’ physical activity, mood, and rest tracking, and (2) caregiver monthly out-of-pocket cost attribute were administered to caregiver respondents. Attributes were parameterized for both digital and non-digital tools. Random utility models were used to estimate caregivers’ preferences and WTP.

Conclusion: Caregivers of SMI patients highly preferred and were willing to pay more for digital tools that not only measures medication ingestion but also tracks general health.

Keywords

Caregiver, serious mental illness, medication adherence, health technology tool, discrete choice experiment

Submission date: 10 August 2021; Acceptance date: 14 February 2022

¹Pear Therapeutics, Inc., Boston, MA, USA
²PRECISIONheor, Los Angeles, CA, USA
³FTI Consulting, Los Angeles, CA, USA
⁴Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA
⁵Optum, Eden Prairie, MN, USA
*At Otsuka Pharmaceutical Development & Commercialization Inc. at time of analysis.
†At PRECISIONheor at time of analysis.

Corresponding author:
Kevin Chiu, PRECISIONheor, 11100 Santa Monica Blvd., Suite 500, Los Angeles, CA 90025, USA.
Email: kevin.chiu@precisionvh.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

In 2019, an estimated 13.1 million adults in the United States (U.S.) were diagnosed with a serious mental illness (SMI).1 SMI includes bipolar disorder (BPD), major depressive disorder (MDD) with psychotic symptoms, treatment-resistant depression, schizophrenia (SCZ), anxiety disorders, eating disorders, and personality disorders with severe functional impairment.1,2 Among them, BPD, MDD and SCZ are commonly diagnosed conditions.2 The estimated annual prevalence rates of BPD, MDD, and SCZ in the U.S is 1.5%, 10.4% and 1.1%, respectively.3-5 BPD is an affective disorder characterized by dramatic shifts in mood, energy, and activity levels.6 MDD is a mood disorder characterized by feelings of sadness, hopelessness, reduced appetite, anxiety, sleep disturbances, and suicidal thoughts.7 SCZ is characterized by symptoms ranging from hallucinations, delusions, reduced emotional expression, motor impairment and cognitive disability.8 Further, the estimated annual economic burden of BPD, MDD and SCZ in the U.S is $195 billion, $325 billion and $155 billion, respectively9-11 with 70–80% of burden attributed to indirect costs that include productivity loss or unemployment by patients or caregivers, missed time at school, medication adherence issues and caregiving support.9,12,13

Patients with SMI face several mental, behavioral and emotional challenges that lead to poor social support, unemployment, medication adherence issues, repeated psychiatric hospitalizations, and susceptibility to other substance use disorders.1 The burden of SMI is not only borne by the patient, but also by caregivers, often unpaid, who spend an average of 32 h a week caring for patients with SMI. Several factors contribute to caregiver burden including lack of social or peer support, limited financial support for their caregiving duties, longevity of caregiving responsibilities, lack of caregiving education, and patients’ poor medication adherence, contributing both to caregiver burden and indirect healthcare costs.12-14

The feasibility and efficacy of digital health interventions across disease areas is well documented. Digital health interventions have been shown to improve disease management,15 patient mental and physical health,16-19 and patient adherence to medications.20 Thus, such interventions have the potential to reduce the burden typically borne by informal caregivers of patients with SMI. In recent years, several health technologies and tools have been developed to measure medication adherence to aid in SMI medication management, including mobile phone applications (apps) that track patients’ self-reported intake of medications,21-23 medical event monitoring systems (MEMS) that electronically track the opening of pill bottles through a device in the cap,24 smart pill dispensers that electronically counts the number of pills dispensed,25 and drug-device combination products that directly track medication ingestion.26 While these technologies have demonstrated effectiveness in improving medication adherence and are highly valued by patients and providers in therapeutic areas including chronic diseases and autoimmune diseases,27-29 the value that caregivers of patients with SMI place on these adherence monitoring tools has not yet been investigated.

The study’s aim was to evaluate the value of digital adherence monitoring tools among informal caregivers of SMI patients by estimating their preferences and willingness to pay (WTP) for these tools compared to non-digital adherence monitoring tools.

Methods

Study population

To evaluate the value to caregivers of different health technology tools designed to aid in monitoring medication adherence, a web-based online survey was administered to informal caregivers who care for patients diagnosed with SMI. An informal caregiver was study-eligible if he/ she was: (1) at least 18 years old; (2) caregiver to a patient diagnosed with one of the three commonly diagnosed SMI conditions -BPD, MDD or SCZ; (3) caregiver to a patient receiving a second-generation oral atypical antipsychotic medication; (4) proficient in English; (5) not formally paid to be a caregiver, (6) able to complete informed consent; and (7) believed that his/her patient had medication adherence issue(s).

Survey instrument

A discrete choice experiment (DCE) was designed to assess caregivers’ preferences for adherence monitoring tools. DCE surveys present respondents with a series of choices with varying attributes and levels to determine how much preferences and WTP vary based on the attributes of interest. These methods are well established in the literature and endorsed by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conjoint Analysis Good Research Practices Task Force for Pharmacoeconomic Research.30-32 As per the ISPOR guidelines, the DCE was designed by identifying all available health technology tools used to monitor medication adherence (referred as technology comparators in the study), by identifying the attributes and their levels that vary between the technology comparators, and by developing the DCE choice sets.

Digital and non-digital health technology tools used to monitor medication adherence currently available in the market were identified through a targeted literature review.23-26,33,34 Among digital health technology tools, four technology alternatives were identified: (1) smart pill...
bottles; (2) smart pill dispensers; (3) mobile apps; and (4) a pill embedded with an ingestible event market (IEM) sensor. A smart pill bottle, such as a MEMS cap, is a cap that fits on standard medicine bottles and records the date, time and number of times the bottle is opened or closed. A smart pill dispenser automatically sorts and organizes pills for daily use, and a few models dispense the pills mechanically. Smart pill bottles and smart pill dispensers share common features in which both track the frequency at which either a pill bottle is opened, or medication is dispensed. Therefore, among the two, only the smart pill dispenser was included as a tool alternative in the DCE. Mobile apps that help caregivers with their duties are commonly used. Some apps remind patients when medication needs to be taken, while others provide external monitoring and send adherence-related data to health care providers or caregivers. Other health-related information is also included in the app and reported to caregivers. Pills embedded with IEM sensors are new digital health tools being utilized in patients with SMI. The sensor embedded in the pill is activated once the medication has been ingested and emits a signal to a patch worn by the patient. The patch is connected to a smartphone app or dashboard via Bluetooth that records the signal upon medication ingestion. Along with capturing medication ingestion information, this technology also tracks other health-related measures, including physical activity (number of steps per day) and rest (time spent resting). Within the smartphone app or dashboard, the patient can also self-report their mood. In turn, caregivers can track these measures to assist with their caregiving duties.

Among non-digital health technology tools, two alternatives were identified: (1) health diaries, and (2) non-digital pill organizer. Health diaries and their use in monitoring medication adherence in mental illness patients have been described in literature, however given that they are open medication adherence in mental illness patients have been described in literature, given that they are open. A smart pill dispenser automatically sorts and organizes pills for daily use, and a few models dispense the pills mechanically. Smart pill bottles and smart pill dispensers share common features in which both track the frequency at which either a pill bottle is opened, or medication is dispensed. Therefore, among the two, only the smart pill dispenser was included as a tool alternative in the DCE. Mobile apps that help caregivers with their duties are commonly used. Some apps remind patients when medication needs to be taken, while others provide external monitoring and send adherence-related data to health care providers or caregivers. Other health-related information is also included in the app and reported to caregivers. Pills embedded with IEM sensors are new digital health tools being utilized in patients with SMI. The sensor embedded in the pill is activated once the medication has been ingested and emits a signal to a patch worn by the patient. The patch is connected to a smartphone app or dashboard via Bluetooth that records the signal upon medication ingestion. Along with capturing medication ingestion information, this technology also tracks other health-related measures, including physical activity (number of steps per day) and rest (time spent resting). Within the smartphone app or dashboard, the patient can also self-report their mood. In turn, caregivers can track these measures to assist with their caregiving duties.

After identifying the technology alternatives, and attributes and associated levels, DCE choice sets comparing two technologies in each choice set were designed using aforementioned attributes without specifying the name of the tool. In many DCEs, choice sets are developed by randomizing all identified attributes across the treatment/technology alternatives to assess participants’ preferences for specific attributes. In this study, the four non-price attributes are likely inter-related and caregiver preferences are likely to exhibit complex attribute interactions. For instance, it is possible that measuring medication adherence digitally may be of low value if this information is not delivered in a timely manner; similarly measuring medication adherence information rapidly may be of low value if it is based on self-reported data. To adjust for non-linear preferences, the four non-price attributes including source of medication adherence information, frequency at which information is updated by the tool, how medication adherence information is accessible to the caregiver, and reporting of patients’ physical activity, mood and quality of rest information were combined into the tools’ attributes bundle (see Table 1). Each choice set comparing two technology alternatives involved randomizing the tools’ attributes bundle and caregiver monthly out-of-pocket cost. The levels for monthly out-of-pocket cost attribute were $10, $40, $120, $200 and calibrated to non-digital pill organizer, mobile app, smart pill dispenser and pill embedded with IEM sensor, respectively. Non-zero dollar amounts were defined for monthly out-of-pocket cost attribute levels as previous studies have shown that free products were not valued the same as non-free goods (See Figure 1). The DCE was designed using the AlgDesign software package for R based on the D-efficiency criteria.

In addition to the DCE module, the survey instrument included an eligibility screener, and additional modules to obtain information on caregiver sociodemographic characteristics, their current use of medication adherence monitoring tools, and their relationship with the patient with SMI that they cared for. The entire survey instrument was designed to be completed in about 20 min.

Data collection

The survey was fielded to a convenience sample of caregivers. We partnered with a survey vendor to recruit potentially eligible participants from their proprietary panels. Participants are recruited into panels through (1) offline methods including phone and in-person recruitment at academic and professional conferences, (2) online methods including targeted e-mail campaigns, social media, direct marketing, and banner placements, (3) using special interest groups, industry associations, and affinity groups, and (4) referrals from other panel members. An invitation to participate in the survey was sent to all participants in the vendor’s panels. Participants who expressed interested
Table 1. Individual and bundled attributes for technology alternatives used in the discrete choice experiment.

| Attributes                          | Bundled attributes | Technology alternatives |
|-------------------------------------|--------------------|-------------------------|
| Source of medication adherence information | Website           | Pill embedded with IEM sensor |
|                                     | Mobile App         | Mobile app              |
| Frequency at which information is updated | Weekly            | Non-digital pill organizer |
|                                     | Daily              |                         |
| How medication adherence information is accessed by caregiver | Device tracked    | Smart pill dispenser     |
| Tools’ attributes bundle            | Patient reported   |                         |
|                                     | Device tracked     |                         |
| Reporting of physical activity information | Device tracked   |                         |
|                                     | Patient reported   |                         |
|                                     | None               |                         |
| Reporting of mood information       | Patient reported   |                         |
|                                     | None               |                         |
|                                     | None               |                         |
| Reporting of rest information       | Device tracked     |                         |
|                                     | None               |                         |
|                                     | None               |                         |
|                                     | None               |                         |
| Monthly out-of-pocket contribution for health technology tool | Monthly out-of-pocket cost | Non-digital pill organizer |
|                                     | $200               |                         |
|                                     | $40                |                         |
|                                     | $120               |                         |
|                                     | $10                |                         |

IEM, ingestible event marker.

were directed to provide their informed consent. Participants who provided informed consent were then asked a series of questions to determine their eligibility. All eligible caregivers were given access to the full survey to provide their responses.

Sample size calculations were conducted using the method described from Louviere et al.39 and it was estimated that \( n = 147 \) caregivers would be sufficient to power the analysis. Equal sample quotas of caregivers were set based on type of SMI diagnoses of the patient for whom they provided care. All eligible caregivers who successfully completed the survey were compensated for their time and effort. The Advarra Institutional Review Board reviewed and approved all study procedures.

### Statistical analysis

Data collected from participants’ responses to the survey instrument were checked for lexicographical preferences. Descriptive analyses were conducted and mean and standard deviations (SD) for continuous variables, and frequencies and proportions for categorical variables were presented. A random parameters logit model was used to estimate the utility weights. A preference weight (reported as odds ratio (OR)) for each technology tool was estimated using the responses to DCE choice sets in the survey. WTP (reported as USD) for each adherence monitoring tool was calculated using the ratio of estimated utility weight of the tools’ attributes bundle and the disutility weight of the monthly out-of-pocket cost attribute. Furthermore, preference shares for the four adherence monitoring tools were assessed.

Preferences and WTP for adherence monitoring tools may differ across caregivers’ subgroups due to the heterogeneous nature of who decides to become a caregiver for a patient with SMI. To address this, subgroup analyses were conducted to evaluate how caregiver preferences and WTP for adherence monitoring tools varied based on (1) SMI diagnosis of the patient, (2) annual household income, and (3) relationship with the patient.

### Results

#### Sample selection

Of the 1320 individuals who indicated interest in participating in the study, 693 failed to either provide informed consent or did not meet the inclusion criteria. Additionally, 246 caregivers who agreed to participate were excluded once a priori sample quotas for each SMI type were met. Of the 381 caregivers who were given full access to the survey, 176 did not provide complete responses and were excluded. The initial study sample
included 205 caregivers who met the study criteria and completed the survey. Twenty-one of these respondents who either took unusual time (<4 min and >2 h) in completing the survey (n = 16) or who reported their patients taking LAIs along with oral atypical antipsychotic medication (n = 5) were further excluded resulting in the final sample of 184 caregivers with complete information. The final 184 analyzed is still well above the 147 required for our study to be sufficiently powered. No caregivers were detected as having lexicographic preferences.

| Features                              | Health Tool A                      | Health Tool B                      |
|---------------------------------------|------------------------------------|------------------------------------|
| Information about medication adherence| Patient-reported                   | Device-tracked                     |
| Accessing information about medication adherence | Mobile application | website |
| Frequency of information updates       | Daily                              | Weekly                             |
| Physical activity information         | Patient-reported                   | No information reported            |
| Mood information                      | No information reported            | No information reported            |
| Rest information                      | Device-tracked                     | No information reported            |
| Caregiver contribution (cost/month)   | $40.00                             | $10.00                             |

Figure 1. Example of discrete choice scenario administered to caregivers in the study.
Table 2. Caregiver sociodemographics, caregiving characteristics, and utilization of adherence monitoring tools, N = 184.

**Sociodemographic characteristics**

| Characteristics                                      | n (%)     | (SD)     |
|------------------------------------------------------|-----------|----------|
| Age, years, mean                                     | 42.2      | 12.9     |
| Gender, n (%)                                        |           |          |
| Male                                                 | 76 (41.3) |          |
| Female                                               | 108 (58.7)|          |
| Race, n (%)                                          |           |          |
| Asian-American                                       | 7 (3.8)   |          |
| African-American                                     | 39 (21.2) |          |
| Caucasian                                             | 126 (68.5)|          |
| Other (Multiple races, Pacific Islander, Native American, or Other) | 11 (6.0) |          |
| Missing                                              | 1 (0.5)   |          |
| Ethnicity, n (%)                                     |           |          |
| Hispanic                                             | 25 (13.6) |          |
| Non-Hispanic                                         | 154 (83.7)|          |
| Missing                                              | 4 (2.7)   |          |
| Highest level of education, n (%)                    |           |          |
| High school or less                                  | 21 (11.4) |          |
| College degree or some college                       | 133 (72.3)|          |
| Graduate degree or some graduate-level education      | 30 (16.3) |          |
| Marital status, n (%)                                |           |          |
| Currently Married or living with partner              | 127 (69.0)|          |
| Widowed, divorced, separated                          | 28 (15.2) |          |
| Single (never married)                               | 29 (15.8) |          |
| Annual household income, n (%)                       |           |          |
| $0–$24,999                                           | 18 (9.8)  |          |
| $25,000–$49,999                                      | 37 (20.1) |          |
| $50,000–$74,999                                      | 37 (20.1) |          |

**Caregiving characteristics**

| Caregiver relationship to patient, n (%)             |          |          |
| Spouse/partner                                       | 55 (29.9)|          |
| Parent                                               | 62 (33.7)|          |
| Child                                                | 26 (14.1)|          |
| Other family membera                                  | 41 (22.3)|          |

**Utilization of adherence monitoring tools**

| Patients’ primary diagnosis, n (%)                   |          |          |
| Bipolar disorder                                     | 57 (31.0)|          |
| Major Depressive Disorder                           | 61 (33.2)|          |
| Schizophrenia                                        | 66 (35.9)|          |

| Caregivers’ use of adherence monitoring tools, n (%) |          |          |
| Yes                                                  | 118 (64.1)|          |
| No                                                   | 66 (35.9) |          |

| Tool used to monitor medication adherenceb,c, n (%)   |          |          |
| Diary                                                | 54 (45.8)|          |
| MEMS cap                                             | 6 (5.1)  |          |
| Mobile app                                           | 35 (29.7)|          |
| Non-digital pill organizer                           | 74 (62.7)|          |
| Paper and pencil                                     | 33 (28)  |          |
| Pill embedded with IEM sensor                        | 23 (19.5)|          |
| Smart pill dispenser                                 | 20 (16.9)|          |
| Smart pill organizer                                 | 52 (44.1)|          |

| Frequency at which tool was checked to monitor patients’ medication intakec, n (%) |          |          |
| Check device daily                                   | 101 (85.6)|          |
Table 2. Continued.

| Time spent per day using tool to monitor patients’ medication intake, n (%) |  |
|---|---|
| <5 min | 16 (13.6) |
| 5–10 min | 36 (30.5) |
| 11–20 min | 23 (19.5) |
| 21–30 min | 29 (26.6) |
| 31–60 min | 7 (5.9) |
| 1–2 h | 7 (5.9) |

IEM, Ingestible Event marker; MEMS, Medication Event Monitoring System.

A majority of caregivers were female (59%), Caucasian (69%), married (69%), had some college education (72%), and reported >$75,000 mean annual household income (47%). One-third of caregivers were parents of the patients with SMI, 30% were spouses/partners, 14% were children, and 22% were other types of family members. It should be noted that we did not purposively exclude non-family members from participation in the survey, and potential participants could also include friends, neighbors, or other unpaid caregivers. However, the analytic sample ultimately included participants who reported being related to the individual with SMI. Among the 184 caregivers, 57 (31%), 61 (33%) and 66 (36%) provided care to patients diagnosed with BPD, MDD and SCZ, respectively. Sixty four percent of the caregivers reported using medication adherence tools, and among them, 85% used the tools daily. In addition, although not mutually exclusive, a majority of caregivers reported using a non-digital pill organizer (63%), followed by diary (46%), smart pill organizer (44%), mobile app (30%) and paper and pencil (28%) (Table 2).

Caregivers’ preferences for digital adherence monitoring tools

Overall, caregivers highly preferred digital adherence monitoring tools as compared to non-digital. The disutility weight of the out-of-pocket cost was 0.0078 (95% confidence interval (CI): 0.011, 0.0038). Caregivers of patients with SMI highly preferred (OR 7.34, 95% CI: 5.00–10.79) a pill embedded with IEM sensor and were willing to pay $255.04 (95% CI $123.21–$386.86) per month more for this tool than a non-digital pill organizer. Similarly, caregivers had 2.64 times higher preference (95% CI: 1.90–3.70) with a WTP $124.50 (95% CI: $48.18–$200.81) per month more for a mobile app relative to a non-digital pill organizer. The smart pill organizer was found to be less preferred by caregivers (OR 0.54 95% CI: 0.40–0.73) with a WTP of –$78.40 (95% CI: –$129.88, –$26.92) per month, which can be interpreted as needing to pay a caregiver $78.40 per month to use the smart pill dispenser (Table 3).

When stratified by primary diagnosis, caregivers of patients with BPD and MDD highly preferred a pill embedded with IEM sensor (OR 7.47, 95% CI: 3.81–14.65 for BPD; OR: 9.79, 95% CI: 4.81–19.9 for MDD). They were willing to pay more for a pill compared to the non-digital pill organizer [$197.48/month (95% CI: $50.91–$344.04) among caregivers of BPD patients, and $227.76/month (95% CI: $66.04–$389.47) among caregivers of MDD patients]. Caregivers of patients with SCZ also highly preferred a pill embedded with IEM sensor (OR 6.71, 95% CI 3.29–13.69), but the WTP was not found to be statistically significant when compared to the non-digital pill organizer. The inability to find statistically significant results is likely because the subgroup analyses are underpowered. The power sample calculation found that 147 individuals per subgroup would be needed for the analyses to be fully powered. Further, subgroup analyses by relationship found that parents, spouses, or child caregivers of patients with SMI highly preferred a pill embedded with IEM sensor than a non-digital pill organizer. However, WTP was found to be significant only for children of the patient, where they were willing to pay $227.27 (95% CI: $15.78–$438.76) per month more for the pill with IEM sensor than a non-digital pill organizer. Compared to a non-digital pill organizer, higher preferences and WTP for a pill embedded with IEM sensor was found among caregivers irrespective of income groups (Supplementary Table 1).

Based on these preferences, a plurality of caregivers preferred a pill embedded with IEM sensor. Specifically, 39.5% of caregivers preferred a pill embedded with IEM sensor followed by a mobile app (26.6%) and a non-digital pill organizer (23.8%) (Figure 2).

Discussion

To our knowledge, this is the first study to estimate preferences and WTP for medication adherence monitoring tools among caregivers of SMI patients. Previous studies have demonstrated the value of medication adherence measurement tools in other diseases.40–43; however, evidence in the SMI space and in particular from the informal caregiver’s
perspective is limited. Effective psychopharmacotherapy requires patients with SMI to take their medication consistently. However, it is often difficult for caregivers to track medication adherence of these patients.44,45 Advancements in medical technology have resulted in the emergence of novel health technology tools that track medication adherence through data on pill ingestion.26 In this study, caregivers highly preferred a pill embedded with IEM sensor that tracks not only medication ingestion but also tracks patients’ physical activity, quality of rest, and self-reported mood. They were willing to pay $255 per month more for this tool than the non-digital pill organizer.

Non-adherence to medication remains a major obstacle to improving health outcomes among patients with SMI, contributing to significant direct and indirect costs.13,46 Underlying SMI condition and symptom severity, social support, socioeconomic status, complexity of adherence interventions, and heterogeneous beliefs in measurement of adherence adds to the complexity of understanding medication non-adherence among these patients.45,47,48 Previous studies have demonstrated that digital health tools have the ability to improve medication adherence in several therapeutic areas including cardiovascular diseases, diabetes and other chronic conditions, and rare autoimmune

| Medication adherence monitoring tool | Odds ratio (95% CI) | Willingness to pay (95% CI) |
|-------------------------------------|----------------------|-----------------------------|
| Pill embedded with IEM sensor      | 7.34* (5.00–10.79)   | $255.04* ($123.21–$386.86)  |
| Mobile app                          | 2.64* (1.90–3.70)    | $124.50* ($48.18–$200.81)   |
| Smart pill dispenser                | 0.54* (0.40–0.73)    | −$78.40* (−$129.88 to −$26.92) |
| Non-digital pill organizer (Referent Group) |                      |                             |

IEM means Ingestible Event Marker; *P-value < 0.05.

Figure 2. Preference shares of different health technology tools used to monitor medication adherence among caregivers in the study.

Table 3. Caregivers’ preferences and willingness to pay for different health technology tools to monitor medication adherence.
diseases. Furthermore, evidence has been emerging on the value of adherence monitoring tools in clinical practice among patients and providers. However, evidence on the value of such tools from caregiver perspective is lacking, and the current study address this gap.

The study findings demonstrated that caregivers preferred and were willing to pay more for a digital health tool that tracked medication ingestion and SMI patients’ general health compared to a non-digital pill organizer. These findings are consistent with previous studies evaluating caregiver preferences for digital health tools for caregiving of individuals diagnosed with chronic diseases or behavioral conditions. A contingent valuation study of caregivers of patients with dementia found a positive WTP for new technologies that aid in conversations with their patients and provide medication reminders. In addition, caregivers who were children of patients with SMI highly preferred and were willing to pay more for a pill embedded with IEM sensor and a mobile app, which can be attributed to their age. Younger individuals are likely to be more comfortable using and be willing to pay for digital adherence tools than non-digital tools. In general, all caregivers in the study, irrespective of their relationship with their SMI patient, highly preferred the pill embedded with IEM sensor to monitor medication adherence in their patients. Overall, the study findings demonstrated the value that caregivers place on digital adherence monitoring tools that track medication ingestion along with other general health measures.

Although evidence is emerging to support the value of digital health technologies in SMI and other disease areas, little research has been conducted on the broader economic impact of these interventions. More research is needed to better understand their benefit and sustainability to quantify their potential cost-savings. While this study does not directly estimate the broader economic impact of digital health tools used for medication adherence, the positive estimates of value indicates that digital health tools are could potentially have an impact on cost-savings or decreasing burden. Future research on the estimating the magnitude of burden reduction or cost-savings is generated from digital health tools is needed.

Ultimately, caregivers’ preferences and value for these technologies are only one stakeholder perspective on the overall value of digital health technologies. While this study was focused on caregivers, capturing patient input remains critical not only for the valuation and development of digital health technologies but to ensure long- and short-term engagement. Several studies have sought to incorporate patient input around specific features associated with digital health technologies across disease areas suggesting that patients prefer digital health technologies primarily for its convenience and communication. In the SMI space, a recent qualitative study of patients with SMI, found that with respect to digital health tools, data privacy is a major concern for patients with SMI. Additional work should be conducted to capture the perspectives of and preferences for features and attributes of digital health technologies among patients diagnosed with SMI.

Strengths and limitations

We believe that this study is the first to attempt to quantify caregiver WTP for digital health technology. The discrete choice experiment approach employed is a well-established methodology for quantifying preferences for digital health technology while removing external decisional influences. As such, this approach is better suited to determine preferences than a real-world study of treatment patterns. For example, a caregiver may not have a smartphone or access to internet; thus, the real cost of using an app would be higher for individuals without a smartphone or internet access compared to those with access to such technologies. Measuring the actual consumption behavior may not detect an individual’s inherent preferences of the goods. The hypothetical choice sets presented in a DCE allows the observation of an actual choice, as the cost of the good is similarly experienced by all participants, which allows for a more accurate estimate of preferences.

The study has several limitations that merit discussion. First, this study bundled individual attributes into tools’ attributes bundle prior to randomization, which allowed us to account for nonlinearities between specific tool features. This approach, however, prevented us for being able to estimate the preferences and WTP for individual attributes separate from the tools’ attributes bundle. Second, the DCE methodology requires the respondent to make hypothetical decisions by evaluating the trade-offs between attributes in a choice set, which differs from real-world scenarios where a myriad of other factors influence preferences and demand. Despite this inherent limitation, the need for DCEs in health care technology assessment continues to grow and is one of the frequently used methodologies to generate evidence in treatment decision-making. Third, our study only examined U.S. caregivers of patients with SCZ, BPD or MDD, and thus the results may not be extrapolated to caregivers of patients with other types of mental illness, other chronic medical conditions or caregivers in other countries or paid caregivers. Fourth, our study only included caregivers of patients with SMI and receipt of second generation oral atypical antipsychotics as inclusion criteria, thus the results may not be extrapolated to caregivers of patients on other antipsychotic or antidepressant medications. Fifth, caregivers in our study were recruited through convenience samples from the survey vendor’s proprietary panels, limiting the generalizability of the study findings to all caregivers who care patients with SMI. Related to the recruitment, while this study did allow for non-family
informal caregivers to participate in the study, our analytical sample coincidentally ended up with only family informal caregivers. While family members are most likely to be informal caregivers, we acknowledge our final sample may not be representative of informal caregivers in the real world setting.

Finally, the nature of our recruitment methods meant that respondent caregivers had access to the Internet. Further, the caregivers were generally highly educated, predominately White, and relatively high income. Thus, this group may not be fully representative of the US population of SMI caregivers. However, in our subgroup analysis, we did find that lower-income caregivers had a positive and statistically significant WTP for the pill with IEM. While our sample does draw upon participants with higher incomes, WTP would likely still remain positive if our sample had included more lower-income respondents. Despite these limitations, the study adds considerable value to the literature on caregiving, medication adherence among patients diagnosed with SMI and value of new technological advances in clinical decision-making.

Conclusion

Compared to a non-digital pill organizer, caregivers of patients with SMI had 7.3 times higher preference for a pill embedded with IEM sensor that tracks not only medication ingestion but also patients’ physical activity, quality of rest and self-reported mood, and were willing to pay $255 per month more for this tool. The study findings suggest that caregivers of patients with SMI place a high value on digital medication adherence monitoring tools. Future research studies could consider examining which specific aspects of new digital technologies are most valuable to the caregivers and identify opportunities and barriers to adoption of medication adherence monitoring digital tools in clinical care management.

Acknowledgements: The authors would like to thank all participants who participated in the study. In addition, the authors would like to acknowledge Richard Murphy, Natalie Land, and Kelly Birch at PRECISIONheor for their assistance in drafting the manuscript.

Author contributions: All authors contributed to one or major sections of the study. The study was conceptualized and designed by FF, KC, JS, and PV. Survey administration, data collection, management and analyses, and results interpretation were conducted by KC and PV with support from JS, DH and FF. PV drafted the manuscript draft with support from KC, JS, DH, and FF. All authors contributed to manuscript revisions and approved the final manuscript draft.

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PRECISIONheor received funding from Otsuka Pharmaceutical Development & Commercialization Inc. to conduct this research. KC is an employee of PRECISIONheor, PV and JS are former employees of PRECISIONheor. DH is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc., and FF is a former employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Otsuka Pharmaceutical Development & Commercialization Inc.

Ethics approval: The study received approval from Advarra Institutional Review Board.

Informed consent: Informed consent was obtained from participants prior to enrollment and survey administration.

ORCID iD: Kevin Chiu https://orcid.org/0000-0003-2584-3736

Trial registration: Not applicable, because this article does not contain any clinical trials.

Guarantor: KC.

Supplemental material: Supplemental material for this article is available online.

References

1. National Institute of Mental Health. Mental Illness, https://www.nimh.nih.gov/health/statistics/mental-illness.shtml (2021, accessed 5 April 2021).
2. American Psychiatric Association. What Is Mental Illness?, https://www.psychiatry.org/patients-families/what-is-mental-illness (2018, 2021).
3. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50: 85–94.
4. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 2018; 75: 336–346.
5. Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the national epidemiologic survey on alcohol and related conditions – III. J Psychiatr Res 2017; 84: 310–317.
6. Carvalho AF, Firth J and Vieta E. Bipolar disorder. N Engl J Med 2020; 383: 58–66.
7. National Institute of Mental Health. Major Depression, https://www.nimh.nih.gov/health/statistics/major-depression (2021, accessed 15 June 2021).
8. National Institute of Mental Health. Schizophrenia. https://www.nimh.nih.gov/health/statistics/schizophrenia (2021, accessed 24 June 2021).

9. Bessonova L, Ogden K, Doane MJ, et al. The economic burden of bipolar disorder in the United States: a systematic literature review. *Clinicoecon Outcomes Res* 2020; 12: 481–497.

10. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). *Pharmacoconomics* 2021; 39: 653–665.

11. Wander C. Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. *Am J Manag Care* 2020; 26(Suppl): S62–S68.

12. Tajima-Pozo K, de Castro Oller MJ, Lewczuk A, et al. Understanding the direct and indirect costs of patients with schizophrenia. *F1000Res* 2015; 4: 182.

13. Bagalman E, Yu-Isenberg KS, Durden E, et al. Indirect costs associated with nonadherence to treatment for bipolar disorder. *J Occup Environ Med* 2010; 52: 478–485.

14. Roth RM, Koven NS, Pendergrass JC, et al. Apathy and the processing of novelty in schizophrenia. *Schizophr Res* 2008; 98: 232–238.

15. Badawy SM, Cronin RM, Hankins J, et al. Patient-centered eHealth interventions for children, adolescents, and adults with sickle cell disease: systematic review. *J Med Internet Res* 2018; 20: e10940.

16. Ramsey WA, Heidelberg RE, Gilbert AM, et al. Ehealth and mHealth interventions in pediatric cancer: a systematic review of interventions across the cancer continuum. *Psycho-oncology* 2020; 29: 17–37.

17. Radovic A and Badawy SM. Technology use for adolescent health and wellness. *Pediatrics* 2020; 145(Supplement 2): S186–S194.

18. Badawy SM and Kuhns LM. Texting and mobile phone app interventions for improving adherence to preventive behavior in adolescents: a systematic review. *JMIR Mhealth Uhealth* 2017; 5: e50.

19. Shah AC and Badawy SM. Telemedicine in pediatrics: systematic review of randomized controlled trials. *JMIR Pediatrics and Parenting* 2021; 4: e22696.

20. Badawy SM, Barrera L, Sinno MG, et al. Text messaging and mobile phone apps as interventions to improve adherence in adolescents with chronic health conditions: a systematic review. *JMIR Mhealth Uhealth* 2017; 5: e7798.

21. Zhu X, Li M, Liu P, et al. A mobile health application-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. *Arch Psychiatr Nurs* 2020; 34: 472–480.

22. Rismawan W, Marchira CR and Rahmat I. Usability, acceptability, and adherence rates of mobile application interventions for prevention or treatment of depression: a systematic review. *J Psychosoc Nurs Ment Health Serv* 2021; 59: 41–47.

23. Haase J, Farris KB and Dorsch MP. Mobile applications to improve medication adherence. *Telemed J E Health* 2017; 23: 75–79.

24. AARDEX Group. MEMS Cap Adherence Hardware, https://www.aardexgroup.com/solutions/mems-adherence-hardware (2019, accessed 24 June 2021).

25. Hoffmann C, Schweighardt A, Conn KM, et al. Enhanced adherence in patients using an automated home medication dispenser. *J Healthc Qual* 2018; 40: 194–200.

26. Food Drug Administration. FDA approves pill with sensor that digitally tracks if patients have ingested their medication. En ligne sur https://www.fda.gov/news-events/press-announcements/fda… (2017).

27. Heinemann L, Schramm W, Koenig H, et al. Benefit of digital tools used for integrated personalized diabetes management: results from the PDM-ProValue study program. *J Diabetes Sci Technol* 2020; 14: 240–249.

28. Lapid MI, Atherton PJ, Clark MM, et al. Cancer caregiver: perceived benefits of technology. *Telemed J E Health* 2015; 21: 893–902.

29. Jang M and Song WO. Personal digital assistants: essential tools for preparing dietetics professionals to use new generation information technology. *Nutr Res Pract* 2007; 1: 42–45.

30. Hauber AB, González JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. *Value Health* 2016; 19: 300–315.

31. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. *Value Health* 2011; 14: 403–413.

32. Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. *Value Health* 2013; 16: 3–13.

33. Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: options to consider. *Int J Clin Pharm* 2014; 36: 55–69.

34. Finnell D and Ditz KA. Health diaries for self-monitoring and self-regulation: applications to individuals with serious mental illness. *Issues Ment Health Nurs* 2007; 28: 1293–1307.

35. Velligan DI and Kamil SH. Enhancing patient adherence: introducing smart pill devices. *Ther Deliv* 2014; 5: 611–613.

36. Ahmed I, Ahmad NS, Ali S, et al. Medication adherence apps: review and content analysis. *JMIR Mhealth Uhealth* 2018; 6: e62.

37. Wilson R, Cochrane D, Mihaílidis A, et al. Mobile apps to support caregiver-resident communication in long-term care: systematic search and content analysis. *JMIR aging* 2020; 5: e17136.

38. Shampianier K, Mazar N and Ariely D. Zero as a special price: the true value of free products. *Marketing science* 2007; 26: 742–757.

39. Louviere JJ, Hensher DA and Swait JD. *Stated choice methods: analysis and applications*. Cambridge: Cambridge University Press, 2000.

40. Quisel T, Foschini L, Zbikowski SM, et al. The association between medication adherence for chronic conditions and digital health activity tracking: retrospective analysis. *J Med Internet Res* 2019; 21: e11486.

41. Conway CM and Kelechi TJ. Digital health for medication adherence in adult diabetes or hypertension: an integrative review. *JMIR Diabetes* 2017; 2: e20.

42. Erras A, Shahrvin B, Weinreb RN, et al. Review of glaucoma medication adherence monitoring in the digital health era. *Br J Ophthalmol* 2021; 1–7.

43. Somers C, Grieve E, Lennon M, et al. Valuing mobile health: an open-ended contingent valuation survey of a National Digital Health Program. *JMIR Mhealth Uhealth* 2019; 7: e3.
44. Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 2017; 11: 449–468.
45. Haddad PM, Brain C and Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014; 5: 43–62.
46. Shafrin J, Forma F, Scherer E, et al. The cost of adherence mismeasurement in serious mental illness: a claims-based analysis. Am J Manag Care 2017; 23: e156–e163.
47. Ngoh LN. Health literacy: a barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc (2003) 2009; 49: e132–e146. quiz e147–139.
48. Farooq S and Naeem F. Tackling nonadherence in psychiatric disorders: current opinion. Neuropsychiatr Dis Treat 2014; 10: 1069–1077.
49. Noble K, Brown K, Medina M, et al. Medication adherence and activity patterns underlying uncontrolled hypertension: assessment and recommendations by practicing pharmacists using digital health care. J Am Pharm Assoc (2003) 2016; 56: 310–315.
50. van Mierlo T, Fournier R and Ingham M. Targeting medication non-adherence behavior in selected autoimmune diseases: a systematic approach to digital health program development. PLoS One 2015; 10: e0129364.
51. Manesh R and Dhaliwal G. Digital tools to enhance clinical reasoning. Med Clin North Am 2018; 102: 559–565.
52. Shin JY, Chaar D, Kedroske J, et al. Harnessing mobile health technology to support long-term chronic illness management: exploring family caregiver support needs in the outpatient setting. JMIA Open 2020; 3: 593–601.
53. Anton MT, Jones DJ, Cuellar J, et al. Caregiver use of the core components of technology-enhanced helping the noncompliant child: a case series analysis of low-income families. Cogn Behav Pract 2016; 23: 194–204.
54. O’Philbin L, Woods B and Holmes E. People with dementia and caregiver preferences for digital life story work service interventions. A discrete choice experiment and digital survey. Aging Ment Health 2020; 24: 353–361.
55. Schulz R, Beach SR, Matthews JT, et al. Caregivers’ willingness to pay for technologies to support caregiving. Gerontologist 2016; 56: 817–829.
56. Badawy SM and Kuhns LM. Economic evaluation of text-messaging and smartphone-based interventions to improve medication adherence in adolescents with chronic health conditions: a systematic review. JMIR Mhealth Uhealth 2016; 4: e121.
57. Iribarren SJ, Cato K, Falzon L, et al. What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions. PloS one 2017; 12; e0170581.
58. Badawy SM, Thompson AA and Kuhns LM. Medication adherence and technology-based interventions for adolescents with chronic health conditions: a few key considerations. JMIR Mhealth Uhealth 2017; 5: e202.
59. Badawy SM, Thompson AA and Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer 2016; 63: 848–852.
60. Perski O, Blandford A, West R, et al. Conceptualising engagement with digital behaviour change interventions: a systematic review using principles from critical interpretive synthesis. Transl Behav Med 2017; 7: 254–267.
61. Perski O, Blandford A, Ubhi HK, et al. Smokers’ and drinkers’ choice of smartphone applications and expectations of engagement: a think aloud and interview study. BMC Med Inform Decis Mak 2017; 17: 1–14.
62. Alexander KE, Ogle T, Hoberg H, et al. Patient preferences for using technology in communication about symptoms post hospital discharge. BMC Health Serv Res 2021; 21: 1–11.
63. Dias N, Yamamoto R and Faulkner KG. Preferences and motivational factors for the use of digital technology in real world oncology studies. American Society of Clinical Oncology, (2020): e14119–e14119.
64. Birch KHBD, Roach M and May SG. Medication adherence among patients with serious mental illness: facilitators, barriers, and preferences for managing medication intake. In: Poster presented at: annual meeting of US psych congress, 2021, October 2021, San Antonio, TX.
65. de Bekker-Grob EW, Ryan M and Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ 2012; 21: 145–172.
66. Khan MU, Brien JA and Aslani P. The use of discrete choice experiments in adherence research: a new solution to an old problem. Res Social Adm Pharm 2020; 16: 1487–1492.
67. Council NR. Informal caregivers in the United States: prevalence, caregiver characteristics, and ability to provide care. In: Paper presented at: the role of human factors in home health care: workshop summary, 2010.